Showing 1 - 3 results of 3 for search 'Michael P. Brown', query time: 0.02s Refine Results
  1. 1
    Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®

    Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB® by Vasilios Liapis, Nicole L. Wittwer, William Tieu, Tessa Gargett, Michael P. Brown, Alexander H. Staudacher

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

    Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metast... by Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski

    Published 2023-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.

    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. by Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: